Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

MeDiApp-PCOS: A Mobile Mediterranean Diet App for Women With Polycystic Ovary Syndrome (MeDiApp-PCOS)

31 maja 2026 zaktualizowane przez: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Randomized Controlled Trial of a Mobile Application With Personalized Mediterranean Diet-Based Recommendations in Women With Polycystic Ovary Syndrome

This randomized clinical trial will test whether a mobile application with personalized Mediterranean diet-based recommendations can improve health outcomes in women with polycystic ovary syndrome compared with standard lifestyle advice.

Participants will be assigned to either the mobile application group or the standard lifestyle advice group.

The primary outcomes are change in LDL cholesterol and change in body mass index after 3 months.

Secondary outcomes include changes in metabolic and hormonal measures, quality of life, treatment adherence, and ovulatory function assessed through 6 months.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

60

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły

Akceptuje zdrowych ochotników

Nie

Opis

Inclusion Criteria:

  • Female participants aged 18 to 45 years.
  • Diagnosis of polycystic ovary syndrome (PCOS) with an anovulatory phenotype according to the Rotterdam criteria (2003).

  • Oligo-ovulation or anovulation, defined as menstrual cycle length greater than 35 days or fewer than 8 menstrual periods per year, together with at least one of the following:

    • Clinical and/or biochemical hyperandrogenism.
    • Polycystic ovarian morphology on ultrasound, defined as at least 20 follicles measuring 2 to 9 mm in either ovary and/or ovarian volume of at least 10 cm3.
  • Possession of a smartphone compatible with the study application (Android or iOS).
  • Ability and willingness to use the mobile application and comply with study procedures.
  • Provision of written informed consent before any study-specific procedures are performed.

Exclusion Criteria:

  • Pregnancy or breastfeeding at the time of enrollment.
  • Planning pregnancy during the study period.
  • Type 1 or type 2 diabetes mellitus.
  • Other endocrine disorders that may affect reproductive or metabolic function, including Cushing syndrome, congenital adrenal hyperplasia, androgen-secreting tumors, hyperprolactinemia, or uncontrolled thyroid disease.
  • Severe liver disease, including cirrhosis or liver failure.
  • Severe renal impairment, defined as estimated glomerular filtration rate less than 30 mL/min/1.73 m2.
  • Severe cardiovascular disease, including unstable angina, myocardial infarction within the previous 6 months, or stroke within the previous 6 months.
  • Use within the previous 3 months of medications that may affect body weight, carbohydrate metabolism, androgen status, or reproductive function, including metformin, oral contraceptives, antiandrogens, gonadotropin-releasing hormone agonists or antagonists, clomiphene citrate, glucocorticoids, thiazolidinediones, or weight-loss drugs.
  • Current or past eating disorders, including anorexia nervosa, bulimia nervosa, or binge eating disorder.
  • Mental disorders or cognitive conditions that, in the opinion of the investigator, would preclude safe participation or compliance with study procedures.
  • Participation in another clinical trial within the previous 3 months.
  • Refusal or inability to provide written informed consent.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Badania usług zdrowotnych
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Mobile Application With Personalized Mediterranean Diet-Based Recommendations

Participants randomized to this arm will receive access to a mobile application specifically developed for women with polycystic ovary syndrome.

The application provides personalized dietary recommendations based on the Mediterranean diet, a system for tracking food intake and physical activity, automated feedback and motivational messages, weekly progress reports, and educational materials on PCOS and healthy lifestyle.

Participants will be instructed to use the application daily for 6 months, including completion of nutrition and activity diaries and review of recommendations and feedback.
Behawioralne: Mobile Application-Based Personalized Mediterranean Diet and Lifestyle Intervention

The intervention consists of a mobile application providing personalized Mediterranean diet-based nutrition plans, a food database with nutritional information, automatic calculation of caloric intake and macronutrient composition, monitoring of adherence to the Mediterranean diet, physical activity recommendations (including minimum weekly minutes of moderate aerobic activity and strength training), an activity diary with step tracking, automated feedback and motivational messages, weekly progress reports, push notifications with reminders, and educational materials on PCOS and healthy lifestyle.

Participants are instructed to use the application daily for 6 months, to enter food intake and physical activity, and to review personalized feedback. The intervention aims to optimize dietary habits, increase physical activity, improve metabolic parameters, and support restoration of ovulatory function in women with PCOS.
Aktywny komparator: Standard Lifestyle Advice

Participants randomized to this arm will receive standard written recommendations for lifestyle modification in polycystic ovary syndrome, including principles of the Mediterranean diet, recommended foods and example menus, and physical activity recommendations.

They will receive a one-time consultation with a dietitian at baseline with explanation of the recommendations and will be advised to keep a paper diary of nutrition and physical activity during the follow-up period.

No access to the mobile application will be provided in this arm.
Behawioralne: Standard Lifestyle Advice for PCOS

Standard care consisting of written lifestyle recommendations for women with polycystic ovary syndrome.

This includes printed materials describing the Mediterranean diet (principles, recommended and discouraged foods, example menus), physical activity recommendations, and general educational information on PCOS and the importance of lifestyle changes.

Participants will receive a one-time dietitian consultation at baseline to review the recommendations and will be advised to keep a paper diary of nutrition and physical activity throughout the follow-up period. No digital application or additional feedback system will be provided.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in LDL cholesterol from baseline to 3 months
Ramy czasowe: Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Serum low-density lipoprotein (LDL) cholesterol concentration measured in mmol/L after an overnight fast
Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Change in body mass index (BMI) from baseline to 3 months
Ramy czasowe: Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)
Body mass index calculated as weight (kg) divided by height (m²)
Baseline (Visit 1, Day 0) and Month 3 (Visit 2, Month 3 ± 7 days)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in fasting insulin and HOMA-IR from baseline to 3 months
Ramy czasowe: Baseline (Visit 1) and Month 3 (Visit 2)

Fasting serum insulin (μIU/mL) and insulin resistance assessed by HOMA-IR index, calculated as (fasting glucose × fasting insulin) / 22.5.

Changes will be calculated as values at 3 months (Visit 2) minus baseline values (Visit 1)
Baseline (Visit 1) and Month 3 (Visit 2)
Change in triglycerides and HDL cholesterol from baseline to 3 months
Ramy czasowe: Baseline (Visit 1) and Month 3 (Visit 2)

Fasting serum triglycerides and high-density lipoprotein (HDL) cholesterol measured using standard enzymatic methods.

Changes will be calculated as values at 3 months (Visit 2) minus baseline (Visit 1).
Baseline (Visit 1) and Month 3 (Visit 2)
Proportion of participants achieving at least 5% weight loss at 3 months
Ramy czasowe: Baseline (Visit 1) and Month 3 (Visit 2)

Percentage of participants with a reduction in body weight of ≥5% from baseline to 3 months.

Weight is measured in light clothing without shoes. Proportion will be compared between groups using chi-square or Fisher's exact test.
Baseline (Visit 1) and Month 3 (Visit 2)
Restoration of regular menstrual cycles during 3-6 months
Ramy czasowe: From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)

Proportion of participants who achieve regular menstrual cycles, defined as cycle length 21-35 days, during the period between Month 3 and Month 6 of follow-up.

Information will be collected from menstrual calendars reviewed at Visit 3.
From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)
Frequency of ovulatory cycles during 3-6 months
Ramy czasowe: From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)

Number and proportion of ovulatory cycles per participant during the period from Month 3 to Month 6.

Ovulation will be confirmed by serum progesterone >5 ng/mL on cycle days 21-23 and/or by ultrasound follicle monitoring when indicated.
From Month 3 to Month 6 (assessed at Visit 3, Month 6 ± 7 days)
Adherence to mobile application use at 3 months (main group only)
Ramy czasowe: From Day 0 to Month 3
Adherence will be assessed as the percentage of days with completed nutrition diaries and the mean Mediterranean diet adherence score calculated automatically by the mobile application over the 3 month period.
From Day 0 to Month 3
Serum total testosterone, free androgen index (calculated), androstenedione and sex hormone-binding globulin (SHBG) measured by immunochemiluminescence assays. Changes will be calculated as 3 month values minus baseline values.
Ramy czasowe: Baseline (Visit 1) and Month 3 (Visit 2)

Serum total testosterone, free androgen index (calculated), androstenedione and sex hormone-binding globulin (SHBG) measured by immunochemiluminescence assays.

Changes will be calculated as 3 month values minus baseline values.
Baseline (Visit 1) and Month 3 (Visit 2)
Change in inflammatory markers: IL-5, Il-22, IL-1 RA,MCP-1, CCL-7 from baseline to 3 months
Ramy czasowe: Baseline (Visit 1) and Month 3 (Visit 2)
Inflammatory markers measured using standard assays. Changes are defined as 3 month values minus baseline values.
Baseline (Visit 1) and Month 3 (Visit 2)
Change in Mediterranean diet adherence score (15-Items Pyramid based Mediterranean Diet Score (PyrMDS)) from baseline to 3 months
Ramy czasowe: Baseline (Visit 1) and Month 3 (Visit 2)

Final score: 0-15

  • 0-5 points - Low adherence to the Mediterranean diet
  • 6-9 points - Moderate adherence to the Mediterranean diet
  • 10-12 points - Good adherence to the Mediterranean diet
  • 13-15 points - High adherence to the Mediterranean diet
Baseline (Visit 1) and Month 3 (Visit 2)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

13 maja 2026

Zakończenie podstawowe (Szacowany)

30 grudnia 2028

Ukończenie studiów (Szacowany)

30 czerwca 2029

Daty rejestracji na studia

Pierwszy przesłany

13 maja 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 maja 2026

Pierwszy wysłany (Rzeczywisty)

20 maja 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

3 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

31 maja 2026

Ostatnia weryfikacja

1 maja 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 125042105343-8

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj